Recent Updates
Recently added Catalysts
IPHA Neutral Sentiment

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

Tuesday, October 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Innate Pharma announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial data readout to the first half of 2027. This change reflects the event-driven nature of the study, which evaluates durvalumab in combination with monalizumab or oleclumab. The previous expectation was for a readout in the second half of 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • PACIFIC-9 trial is ongoing and under evaluation.
  • The study is led by AstraZeneca, a reputable company.

CONCERNS & RISKS

  • Data readout timing has been pushed back to H1 2027.
  • Initial expectations were for a readout in H2 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
7%
average across 4 past catalysts
Lead asset
IPH5201
Phase 2 · Non Small Cell Lung Cancer

Full Press Release Details

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study. PACIFIC-9 is an AstraZeneca-led Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclum

Frequently Asked Questions

What is the PACIFIC-9 trial?

The PACIFIC-9 trial evaluates durvalumab with monalizumab or oleclumab.

When is the new readout timing for PACIFIC-9?

The readout is now expected in the first half of 2027.

Who is leading the PACIFIC-9 trial?

The trial is led by AstraZeneca.

Why was the readout timing updated?

The timing was updated due to the event-driven nature of the study.

ShareAdd on Google
Tags: IPHA Innate Pharma AstraZeneca PACIFIC-9 durvalumab monalizumab
Last updated: Oct 27, 2026

Biotech snapshot

Lead asset
IPH5201Phase 2
Non Small Cell Lung Cancer →

Catalyst track record

+35%
best trade around IPHA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for IPHA.

See every catalyst's timing & PoA →